# Avidity Partners Management LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1791827. Source: https://holderbook.com/funds/1791827-avidity-partners-management-lp/

- Reported value: $624.4M
- Positions: 45
- Weight of the ten largest: 81.9%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| DIANTHUS THERAPEUTICS INC | [DNTH](https://holderbook.com/stocks/DNTH/) | $205.1M | 2,104,184 | 32.8% | 12 |
| CG ONCOLOGY INC | [CGON](https://holderbook.com/stocks/CGON/) | $99.4M | 1,398,948 | 15.9% | 10 |
| ORUKA THERAPEUTICS INC | [ORKA](https://holderbook.com/stocks/ORKA/) | $72.4M | 760,424 | 11.6% | 8 |
| JADE BIOSCIENCES INC | [JBIO](https://holderbook.com/stocks/JBIO/) | $37.8M | 1,700,708 | 6.1% | 5 |
| ENLIVEN THERAPEUTICS INC | [ELVN](https://holderbook.com/stocks/ELVN/) | $27.9M | 550,000 | 4.5% | 6 |
| PERSPECTIVE THERAPEUTICS INC | [CATX](https://holderbook.com/stocks/CATX/) | $21.5M | 6,299,999 | 3.4% | 9 |
| AKTIS ONCOLOGY INC | [AKTS](https://holderbook.com/stocks/AKTS/) | $15.6M | 484,200 | 2.5% | 2 |
| PALVELLA THERAPEUTICS INC NE | [PVLA](https://holderbook.com/stocks/PVLA/) | $10.7M | 70,000 | 1.7% | 3 |
| MOBIA MED INC | - | $10.7M | 798,282 | 1.7% | 1 |
| REPLIGEN CORP | [RGEN](https://holderbook.com/stocks/RGEN/) | $10.6M | 77,800 | 1.7% | 5 |
| IMMUNIC INC | [IMUX](https://holderbook.com/stocks/IMUX/) | $10.3M | 669,941 | 1.6% | 1 |
| SENSEONICS HLDGS INC | [SENS](https://holderbook.com/stocks/SENS/) | $9.1M | 1,600,000 | 1.5% | 1 |
| KARYOPHARM THERAPEUTICS INC | [KPTI](https://holderbook.com/stocks/KPTI/) | $9.0M | 924,487 | 1.4% | 6 |
| TEVA PHARMACEUTICAL INDS LTD | [TEVA](https://holderbook.com/stocks/TEVA/) | $6.8M | 200,000 | 1.1% | 6 |
| DEXCOM INC | [DXCM](https://holderbook.com/stocks/DXCM/) | $6.7M | 100,000 | 1.1% | 2 |
| TEMPUS AI INC | [TEM](https://holderbook.com/stocks/TEM/) | $6.1M | 105,000 | 1.0% | 2 |
| MEDTRONIC PLC | [MDT](https://holderbook.com/stocks/MDT/) | $5.5M | 70,000 | 0.9% | 4 |
| VIR BIOTECHNOLOGY INC | [VIR](https://holderbook.com/stocks/VIR/) | $5.3M | 519,300 | 0.8% | 2 |
| STRUCTURE THERAPEUTICS INC | [GPCR](https://holderbook.com/stocks/GPCR/) | $5.3M | 98,000 | 0.8% | 2 |
| ENCOMPASS HEALTH CORP | [EHC](https://holderbook.com/stocks/EHC/) | $4.2M | 42,000 | 0.7% | 5 |
| TENAX THERAPEUTICS INC | [TENX](https://holderbook.com/stocks/TENX/) | $3.9M | 265,934 | 0.6% | 2 |
| NUVECTIS PHARMA INC | [NVCT](https://holderbook.com/stocks/NVCT/) | $3.7M | 200,000 | 0.6% | 1 |
| INSULET CORP | [PODD](https://holderbook.com/stocks/PODD/) | $3.7M | 24,000 | 0.6% | 2 |
| BOSTON SCIENTIFIC CORP | [BSX](https://holderbook.com/stocks/BSX/) | $3.4M | 80,000 | 0.5% | 18 |
| SATELLOS BIOSCIENCE INC | [MSLE](https://holderbook.com/stocks/MSLE/) | $3.0M | 387,769 | 0.5% | 2 |
| ALAMAR BIOSCIENCES INC | [ALMR](https://holderbook.com/stocks/ALMR/) | $3.0M | 110,000 | 0.5% | 1 |
| CONTEXT THERAPEUTICS INC | [CNTX](https://holderbook.com/stocks/CNTX/) | $2.8M | 4,998,267 | 0.4% | 9 |
| GILEAD SCIENCES INC | [GILD](https://holderbook.com/stocks/GILD/) | $2.5M | 20,000 | 0.4% | 2 |
| CHARLES RIV LABS INTL INC | [CRL](https://holderbook.com/stocks/CRL/) | $2.3M | 10,000 | 0.4% | 2 |
| PHATHOM PHARMACEUTICALS INC | [PHAT](https://holderbook.com/stocks/PHAT/) | $2.2M | 200,000 | 0.3% | 19 |
| AVALYN PHARMACEUTICALS INC | [AVLN](https://holderbook.com/stocks/AVLN/) | $2.0M | 60,000 | 0.3% | 1 |
| KAILERA THERAPEUTICS INC | [KLRA](https://holderbook.com/stocks/KLRA/) | $1.8M | 80,000 | 0.3% | 1 |
| GENMAB A/S | [GMAB](https://holderbook.com/stocks/GMAB/) | $1.4M | 50,000 | 0.2% | 6 |
| INTELLIA THERAPEUTICS INC | [NTLA](https://holderbook.com/stocks/NTLA/) | $1.3M | 75,000 | 0.2% | 2 |
| CORVUS PHARMACEUTICALS INC | [CRVS](https://holderbook.com/stocks/CRVS/) | $1.2M | 80,000 | 0.2% | 2 |
| ODDITY TECH LTD | [ODD](https://holderbook.com/stocks/ODD/) | $1.1M | 70,000 | 0.2% | 2 |
| SCYNEXIS INC | - | $1.1M | 260,206 | 0.2% | 1 |
| EVOMMUNE INC | [EVMN](https://holderbook.com/stocks/EVMN/) | $996.8K | 75,000 | 0.2% | 1 |
| ABBOTT LABORATORIES | [ABT](https://holderbook.com/stocks/ABT/) | $907.4K | 10,000 | 0.1% | 2 |
| BRIDGEBIO PHARMA INC | [BBIO](https://holderbook.com/stocks/BBIO/) | $744.8K | 10,000 | 0.1% | 2 |
| PELOTON INTERACTIVE INC | [PTON](https://holderbook.com/stocks/PTON/) | $591.0K | 100,000 | 0.1% | 2 |
| LEGEND BIOTECH CORP | [LEGN](https://holderbook.com/stocks/LEGN/) | $433.2K | 15,000 | 0.1% | 2 |
| BRIDGEBIO ONCOLOGY THERAPEUT | [BBOT](https://holderbook.com/stocks/BBOT/) | $334.2K | 43,853 | 0.1% | 2 |
| SAVARA INC | [SVRA](https://holderbook.com/stocks/SVRA/) | $308.0K | 50,000 | 0.0% | 2 |
| TREVI THERAPEUTICS INC | [TRVI](https://holderbook.com/stocks/TRVI/) | $124.2K | 6,660 | 0.0% | 2 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +20.8% | +14.8% | +6.0% | 94% |
| Q1 2026 | +40.4% | -4.6% | +45.0% | 100% |
| Q4 2025 | +12.4% | +2.4% | +10.0% | 98% |
| Q3 2025 | +19.2% | +7.8% | +11.4% | 99% |
| Q2 2025 | +1.6% | +10.5% | -8.8% | 94% |
| Q1 2025 | -13.5% | -4.6% | -9.0% | 99% |
| Q4 2024 | -12.2% | +2.1% | -14.4% | 100% |
| Q3 2024 | +9.1% | +5.4% | +3.6% | 99% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $624.4M | 45 |
| Q1 2026 | $935.7M | 52 |
| Q4 2025 | $346.7M | 39 |
| Q3 2025 | $439.4M | 43 |
| Q2 2025 | $502.0M | 55 |
| Q1 2025 | $524.7M | 64 |
| Q4 2024 | $1.0B | 62 |
| Q3 2024 | $2.0B | 81 |
| Q2 2024 | $2.4B | 85 |
| Q1 2024 | $3.1B | 87 |
| Q4 2023 | $2.7B | 73 |
| Q3 2023 | $2.5B | 83 |